Table I.

Description of populations included in the analysis

	Control source	Study site	Cases	Controls	GSTM1		GSTT1
					% Null in controls	OR (95% CI)	% Null in controls	OR (95% CI)
African-American
Rebbeck (30,31)	Clinic	PA	41	123	28.5	0.73 (0.46–1.15)	40.5	0.74 (0.49–1.11)
Lavender (32)a	Clinic	DC	188	637	30.3	1.02 (0.81–1.28)	22.0	1.21 (0.93–1.57)
Parka	Clinic	FL	61	61	13.3	1.52 (0.95–2.43)	––	––
Taioli	Healthy volunteers	NY	30	32	21.9	0.95 (0.51–1.74)	––	––
Agalliu (29)a	Healthy	WA	147	84	31.7	0.84 (0.47–1.50)	27.4	0.74 (0.40–1.37)
OR (95 % CI)b			467	937		1.0 (0.85 –1.19)c		1.01 (0.78–1.24)d
Caribbean
Bunkera	Healthy	Tobago	277	449	25.6	0.91 (0.76–1.08)	30.3	0.97 (0.82–1.14)
Jacksona	Clinic	Jamaica	128	145	26.2	1.07 (0.82–1.40)	35.2	0.95 (0.74–1.22)
Mallick (28)a	Clinic	Guadeloupe	134	134	26.9	0.65 (0.37–1.16)	36.6	0.50 (0.29–0.86)
Romanaa	Population	Guadeloupe	629	622	31.7	0.85 (0.76–0.95)	30.9	0.82 (0.73–0.92)
OR (95 % CI)b			1168	1350		0.88 (0.81–0.96)e		0.86 (0.79–0.94)f
Africa
Lavender (32)a	Clinic	USA	14	21	25.0	0.74 (0.30–1.83)	25.0	0.55 (0.17–1.72)
Ukoli	Healthy	Nigeria	66	55	23.6	0.71 (0.45–1.14)	40.0	0.93 (0.64–1.34)
OR (95 % CI)b			80	76		0.72 (0.47–1.08)		0.89 (0.62–1.26)
Totalb			1715	2363		0.90 (0.83–0.97)g		0.88 (0.82–0.96)h

^aDNA extracted from peripheral blood.

^bAdjusted for study, age (quartiles) and smoking(ever/never); meta ORs from fixed models are reported.

^cQ-test P-value: 0.261; I² (%): 24% (0.0–69.0); Eggers-Test P-value: 0.828

^dQ-test P-value: 0.081; I² (%): 60% (0.0–89.0); Eggers-Test P-value: 0.330.

^eQ-test P-value: 0.303; I² (%): 18% (0.0–87.0); Eggers-Test P-value: 0.828.

^fQ-test P-value: 0.068; I² (%): 58% (0.0–86.0); Eggers-Test P-value: 0.683.

^gQ-test P-value: 0.294; I² (%): 16% (0.0–56.0); Eggers-Test P-value: 0.883.

^hQ-test P-value: 0.066; I² (%): 45% (0.0–75.0); Eggers-Test P-value: 0.593.